References
- Bradley WG, Miller RG and the BDNF Study Group. Phase III trial of subcutaneous recombinant methionyl human BDNF in patients with ALS. Neurology 1999; 52: 1427–1433.
- Miller RG, Moore DH, Gelinas DF et al. Phase III random- ized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–848.
- Trojan DA, Collet JP, Pollak MN et al. Serum IGF-1 does not correlate positively with isometric strength, fatigue and qualify of life in post-polio syndrome. J Neurol Sci 2001; 182: 107–115.
- Mulder DW, Howard FM. Patient resistance and prognosis in amyotrophic lateral sclerosis. Mayo Clin Proc 1976; 51: 537–541.
- Kaplan LM, Hollander D. Respiratory dysfunction in amy- otrophic lateral sclerosis. Clin Chest Med 1994; 15: 675–681.
- Brooke MH, Fenichel GM, Griggs RC et al. Clinical investiga- tion in Duchenne dystrophy: 2. Determination of the ‘power’ of therapeutic trials based on the natural history. Muscle Nerve 1983; 6: 91–103.
- Griggs RC, Donohoe SM, Utell MJ, Goldblatt D, Mosley RT. Evaluation of pulmonary function on neuromuscular disease. Arch Neurol 1981; 38: 9–12.
- Andres PL, Finison LJ, Conlon T, Thibodeau LM, Munsat TL. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 1988; 38: 405–408.
- Miller RG. Rosenberg JA. Gelinas DF et al. Practice parame- ter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52: 1311–1323.
- Fallat RJ, Jewitt B, Bass M, Kamm B, Norris FH. Spirometry in amyotrophic lateral sclerosis. Arch Neurol 1979; 36: 74–80.
- Griggs RC. The use of pulmonary function testing as a quan- titative measurement for therapeutic trials. Muscle Nerve 1990; 13(Suppl): S30–S34.